drugset / Trial / NCT00030966

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966

Phase 3 Completed 1200 enrolled Biogen Elan Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).

Timeline

Start
2002-01
Primary completion
2005-04
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject natalizumab Monoclonal antibody 300 mg Intravenous